Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy…

Overview of attention for article published in Frontiers in oncology, November 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (84th percentile)
High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

twitter: 19 X users

Readers on

mendeley: 34 Mendeley

Summary X

So far, Altmetric has seen 19 X posts from 19 X users, with an upper bound of 54,366 followers.

New article: Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of… https://t.co/uAEzVHvCXw #brea

22 Nov 2019

Reply Repost Favourite

New research: Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data:… https://t.c

18 Nov 2019

Reply Repost Favourite

RT @prat_aleix: ...more evidence regarding the clinical validity of PAM50 subtypes within HER2+ disease. Now we need studies to determine i…

12 Nov 2019

Reply Repost Favourite

RT @prat_aleix: ...more evidence regarding the clinical validity of PAM50 subtypes within HER2+ disease. Now we need studies to determine i…

07 Nov 2019

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 15 additional X posts.